Ingelheim am Rhein

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer, Trichloroethylene, Acquisition, Innovation, Ingelheim am Rhein, Potyvirus, Boehringer Ingelheim, Tissue, Cancer, Innovation Unit, Patient, Bi-specific T-cell engager, Bacteria, Immunotherapy, CHF, Pharma, Fine chemical, Vaccine, Allschwil

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.

Key Points: 
  • Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.
  • T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
  • “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs.
  • Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches.

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Retrieved on: 
Friday, November 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Standard of care, University of Washington School of Medicine, Hyperkalemia, Oxford, Pressure, Albuminuria, SGLT2, Kidney, HIV disease progression rates, Society, American Society of Nephrology, Population 1 (album), Chronic kidney disease, Phase, Boehringer Ingelheim, Clinical trial, ASN, Hypertension, Aldosterone, Risk, Kidney disease, University, Serum, ASI, CKD, Safety, End organ damage, Patient, Ingelheim am Rhein, Pharmaceutical industry, UACR, Medicine

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).

Key Points: 
  • Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
  • “With over 1 billion people worldwide affected by these conditions, the potential to help reduce the pressure on healthcare systems and patients is immense.
  • We are proud to be leading the way in this field and are excited to move forward with the upcoming Phase III trial to further investigate the potential of this novel compound on top of standard of care including empagliflozin."
  • Hyperkalemia occurred at a rate typical for a CKD population,1 and most episodes did not require medical treatment or BI 690517 discontinuation.1

Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study

Retrieved on: 
Saturday, November 4, 2023
Medical Affairs Bureau, Research, Insurance, EGFR, Medicare, Physician, Kidney failure, Glomerular filtration rate, HIV disease progression rates, Society, American Society of Nephrology, Chronic kidney disease, Boehringer Ingelheim, Dialysis, Disease, ASN, Risk, Machine learning, Medicaid, Urinalysis, CKD, Chemistry, Patient, Diagnosis, Ingelheim am Rhein, Cryptocurrency, Pharmaceutical industry, Medical device

Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.

Key Points: 
  • Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.
  • These findings were presented in an oral session at the American Society of Nephrology (ASN) Kidney Week conference in Philadelphia, being held from November 1-5, 2023.
  • Physicians need novel tools to evaluate risk of CKD progression, which could assist with earlier diagnosis and treatment."
  • The Klinrisk model was developed to predict the risk of CKD progression, defined as either a 40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (dialysis, kidney transplant or eGFR below 10 mL/min/1.73 m2).

Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level

Retrieved on: 
Friday, October 6, 2023
Diagnosis, Partnership, Eli Lilly and Company, AKF, Senior, American Kidney Fund, Organization, Risk, Ingelheim am Rhein, Patient, Kidney, All, Advancing American Kidney Health, Kidney disease, Boehringer Ingelheim, Research, Pharmaceutical industry, Lilly

ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.

Key Points: 
  • ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.
  • Boehringer Ingelheim and Lilly’s membership helps fund AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research.
  • “AKF is pleased to continue our partnership with Boehringer Ingelheim and Lilly in the fight against kidney disease,” said LaVarne A. Burton, AKF President and CEO.
  • “Boehringer Ingelheim and Lilly are proud to continue to champion the work of the AKF by joining the Corporate Membership Program for the second consecutive year,” said Brian DiDonato, Senior Vice President, Cardio-Renal-Metabolic Brands at Boehringer Ingelheim.

Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and without Diabetes, Cardiovascular Disease and Chronic Kidney Disease

Retrieved on: 
Thursday, October 5, 2023
Diabetes, Health, Pharmaceutical, Clinical Trials, Cardiology, BMI, European Association for the Study of Diabetes, Multimedia, Hypertension, Obesity, Prevalence, A1C, Ingelheim am Rhein, Disease, Overweight, Principal, Conditional sentence, EASD, Phase, Appetite, Dyslipidemia, Obstructive sleep apnea, BI, Zealand Pharma, Boehringer Ingelheim, University college, Pharmaceutical industry

Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity.

Key Points: 
  • Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity.
  • The trial design builds upon learnings from Phase II, in which people living with overweight or obesity achieved up to 19 percent weight loss.1 The Phase III trials will soon open for recruitment.
  • SYNCHRONIZE-1 will enroll people without type 2 diabetes (A1C
  • The third study, SYNCHRONIZE-CVOT, is a Phase III trial that will enroll people with overweight or obesity with cardiovascular disease, chronic kidney disease, or risk factors for cardiovascular disease.

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Retrieved on: 
Monday, October 2, 2023
Technology, Medical Devices, Professional Services, Biotechnology, Health, Data Analytics, Data Management, Optical, Artificial Intelligence, Neuroprotection, Retina, Ingelheim am Rhein, Partnership, Depression, Ageing, Quality of life, Inflammation, Science, Boehringer Ingelheim, Eye, Patient, Algorithm, Diagnosis, ZEISS, AI, Paratriathlon, Automation, Pharmaceutical industry, Medical imaging, Telescopic sight

Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.

Key Points: 
  • Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.
  • The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs.
  • * The number of people suffering from vision loss is expected to rise due to aging populations and widening health inequity gaps.
  • Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1

Retrieved on: 
Friday, June 23, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ingelheim am Rhein, Obesity, Therapy, Prevalence, Doctor of Philosophy, Glucagon, Weight loss, BI, Multimedia, University college, Appetite, Boehringer Ingelheim, American Diabetes Association, Overweight, Liver, Principal, Phase, Zealand Pharma, Safety, Disease, Pharmaceutical industry, MD

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.

Key Points: 
  • Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.
  • This press release features multimedia.
  • “Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver.
  • “At Zealand Pharma, we have both experience and success in discovering and developing peptide therapeutics that target key metabolic pathways – designed to help people living with overweight and obesity by achieving substantial weight loss while addressing the many complications of this disease.”

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Retrieved on: 
Wednesday, May 10, 2023
Research, Diabetes, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Other Science, Ingelheim am Rhein, Maintenance, Obesity, Therapy, Heart failure, Chronic kidney disease, Prevalence, Hepatology, Liver disease, Weight loss, Multimedia, Boehringer Ingelheim, Patient, American Diabetes Association, CRM, Overweight, Zealand Pharma, Pharmaceutical industry

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose.

Key Points: 
  • Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose.
  • The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint.
  • Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades11.
  • The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society11.

Greater Good Charities, with Boehringer Ingelheim Animal Health & The Animal Rescue Site, Kicks Off 3rd Year of Good Flights & Successful Transport of 8,800+ Shelter Pets to Adoptive Homes Including 900+ Asymptomatic Heartworm-Positive Dogs

Retrieved on: 
Monday, April 3, 2023
Infection, Ingelheim am Rhein, Heart, Save, Transport, Animal rescue, The Hunger Site, National Baptist Convention, USA, Inc., Coccidioides immitis, GA, Associate, Boehringer Ingelheim, Greater good, Euthanasia, Dog, Pet, Cat, Animal Care Centers of NYC, Save a Heart Foundation, Baltimore, Dirofilaria immitis, Ivermectin, Safety, House, DVM, Dirofilaria, Boehringer Ingelheim Animal Health, Disease, Pharmaceutical industry

To kick off the third year of Good Flights, a special transport of more than 100 shelter pets will take place on April 3 from New Orleans, LA.

Key Points: 
  • To kick off the third year of Good Flights, a special transport of more than 100 shelter pets will take place on April 3 from New Orleans, LA.
  • Asymptomatic heartworm-positive shelter dogs transported via Save a Heart receive initial medication, in accordance with the recommendations from the American Heartworm Society, prior to transport.
  • "Heartworm is a devastating disease for dogs and those who care for them, said Julie Ryan-Johnson, DVM, Associate Director of Shelter Programs at Boehringer Ingelheim Animal Health.
  • All shelter pets transported via Good Flights will be handled in compliance with the USDA’s interstate regulations.

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Retrieved on: 
Wednesday, March 29, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Acceleration, Ingelheim am Rhein, Heart failure, Diabetes, Executive officer, Flea, Tax, Finance, Medicine, Animal Health, Inflammation, Boehringer Ingelheim, EUR, Animal, Patient, Investment, Dog, Cat, Growth, FDA, Research and development, Mental health, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Fine chemical

Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.

Key Points: 
  • Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.
  • Boehringer Ingelheim received one Breakthrough Designation, three Fast Track Designations, and two Orphan Drug Designations from the FDA.
  • OFEV® generated net sales of 3.2 billion EUR, representing a currency-adjusted growth of 20.6 percent in 2022.
  • Looking ahead, Boehringer Ingelheim anticipates moderate growth in 2023, on a comparable basis, with a slight increase in its operating income, creating the fundamentals for bringing more innovative medicines to patients and animals.